Condition: Non-Small-Cell Lung Carcinoma · Sponsor: Novartis Pharmaceuticals
This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan) for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry of Food and Drug Safety).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Daegu, Dalseo gu, South Korea | Recruiting |
| Novartis Investigative Site | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Novartis Investigative Site | Incheon, Korea, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, Korea, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, Seoul, South Korea | Recruiting |
| Novartis Investigative Site | Busan, South Korea | Recruiting |
| Novartis Investigative Site | Daejeon, South Korea | Recruiting |
| Novartis Investigative Site | Jeollanam, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05703516